Mason Street Advisors LLC purchased a new stake in shares of PharMerica Corp. (NYSE:PMC) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,008 shares of the company’s stock, valued at approximately $148,000.
A number of other large investors have also made changes to their positions in PMC. Public Employees Retirement System of Ohio increased its stake in shares of PharMerica Corp. by 7.5% in the second quarter. Public Employees Retirement System of Ohio now owns 4,215 shares of the company’s stock valued at $104,000 after buying an additional 293 shares in the last quarter. Teacher Retirement System of Texas increased its stake in PharMerica Corp. by 14.1% in the second quarter. Teacher Retirement System of Texas now owns 4,243 shares of the company’s stock worth $105,000 after buying an additional 523 shares in the last quarter. Springbok Capital Management LLC increased its stake in PharMerica Corp. by 22.8% in the first quarter. Springbok Capital Management LLC now owns 7,000 shares of the company’s stock worth $155,000 after buying an additional 1,300 shares in the last quarter. Sei Investments Co. increased its stake in PharMerica Corp. by 3.8% in the second quarter. Sei Investments Co. now owns 6,638 shares of the company’s stock worth $163,000 after buying an additional 240 shares in the last quarter. Finally, Walleye Trading LLC purchased a new stake in PharMerica Corp. during the second quarter worth $180,000. 92.37% of the stock is owned by institutional investors and hedge funds.
PharMerica Corp. (NYSE:PMC) opened at 27.11 on Friday. The firm has a market cap of $834.01 million, a P/E ratio of 28.01 and a beta of 0.88. PharMerica Corp. has a 1-year low of $19.79 and a 1-year high of $35.81. The company has a 50-day moving average price of $26.93 and a 200-day moving average price of $25.32.
PharMerica Corp. (NYSE:PMC) last announced its quarterly earnings results on Tuesday, August 9th. The company reported $0.47 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.47. PharMerica Corp. had a return on equity of 10.00% and a net margin of 1.44%. The business earned $519.60 million during the quarter, compared to the consensus estimate of $508.31 million. During the same quarter in the prior year, the company posted $0.48 earnings per share. PharMerica Corp.’s revenue was up 4.4% compared to the same quarter last year. On average, equities research analysts forecast that PharMerica Corp. will post $2.01 EPS for the current fiscal year.
Separately, Zacks Investment Research downgraded PharMerica Corp. from a “hold” rating to a “sell” rating in a report on Wednesday, August 17th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. PharMerica Corp. currently has an average rating of “Buy” and a consensus target price of $31.57.
About PharMerica Corp.
PharMerica Corporation is an institutional pharmacy services company. The Company services healthcare facilities, provides pharmacy management services to hospitals, provides specialty infusion services to patients outside a hospital setting and offers the national oncology pharmacy in the United States.
Want to see what other hedge funds are holding PMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PharMerica Corp. (NYSE:PMC).
Receive News & Ratings for PharMerica Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharMerica Corp. and related companies with MarketBeat.com's FREE daily email newsletter.